| August 28, 2014 | ISSUE NUMBER 366 VOL 4 |
|
Generics
Generics and the Canadian-European Trade Agreement: An American Rx View
As a young pharma manager, Tom Norton was involved in America’s “Great Generic Wars”, a struggle between U.S. brand name manufacturers and generic drug producers that lasted almost 30 years before generics won out. So he is watching with interest what Canada is about to visit on its own generic drug industry, courtesy of CETA, a new international trade agreement ...Read more
World Health
The Ebola Debates Turn Everyone Into An Expert
It is a tragic truism to remark that the merits of the pharma sector are most sharply perceived only at times of deep human suffering. The debates engendered by the latest Ebola outbreak demonstrate the point. All of a sudden, the mass media and social networks are reflecting public demands for more action on drug development—instead of the customary complaints that drug firms are merely cynical money-making machines ...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence –  by downloading this eBook.
World Health
Experimental Ebola Drugs Must Be Tested Ethically
Researchers and health authorities need to ensure that experimental drugs to treat Ebola are distributed fairly, and in the context of randomized controlled trials, according to a viewpoint column published in The Lancet. Bioethicists Dr. Ezekiel Emanuel and Dr. Annette Rid outlined critical ethical principles that must be adhered to if experimental drugs are to be deployed in the Ebola outbreak
...Read more
Global
Read the New Pharm Exec Global Digest: Technology Special
In this month’s issue: UBISTART, the US-French payout initiative for new startups; Fixing the Medical Technology Disconnect; the Future of Safety Signal Detection and Risk Management; Wearable Healthcare Technology
...Read more
Emerging Pharma Leaders
Pharm Exec’s Emerging Pharma Leaders 2014
This year's class of 15 young executives is deeply of the moment, with assignments that include advancing therapies against hepatitis C, building new cell-based platforms in regenerative medicine, creating new businesses beyond a protected home base, and transforming raw data into "news I can use" analytics
...Read more
|
|
|
|
 //Thesan Pharmaceuticals (San Diego, CA) appointed Bhaskar Chaudhuri, Ph.D., to its Board of Directors.//Mark Ahn, of Galena Biopharma (Portland, OR) was replaced by Mark W. Schwartz, Ph.D, who takes on the role as President and CEO.//Lion Biotechnologies (Los Angeles, CA) has hired Elma Hawkins, Ph.D, to serve as President and COO.//Biogen Idec (Cambridge, MA) announced the appointment of Adriana (Andi) Karaboutis as Executive Vice President, Technology and Business Solutions, effective September 24.//
|
|
|
|
|
|
 |
|
| |
 |
|
 |
What is your key area of concern regarding your company’s future?
|
|
|
|
